The European healthcare technology and clinical artificial intelligence sectors have transitioned into an era of disciplined industrialisation. The speculative fragmentation and "growth-at-all-costs" investment thesis that characterized the zero-interest-rate policy era have been replaced by a rigorous focus on unit economics, real-world clinical evidence, and deep workflow integration. As the market approaches the second half of 2026, venture capital deployment in clinical A